• New knowledgebase with expert-curated pharmacogenomic content on how genetic variations influence drug response

• Centralized data and automated annotation enable scientific and translational researchers to rapidly generate genomic and drug insights

• Enhancing the understanding of pharmacogenomics is crucial to, reduce treatment-related side effects and optimizing drug development and delivery

Redwood City, California – QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN and the leading provider of bioinformatics software and biomedical knowledge content, today announced the launch of Pharmacogenomic Insights (PGXI), a new knowledgebase designed to help scientific and translational researchers better understand how an individual’s genetic make-up influences their response to medications.

Providing a streamlined and automated approach to how labs can efficiently and confidently produce evidence-backed insights for pharmacogenomic markers, PGXI enables faster, more precise drug development and delivery.

PGXI is a new knowledgebase solution within PGx built upon a legacy platform used to deliver more than 1.6 million PGx annotations for more than 250 clinical research laboratories. The knowledgebase contains data from all established pharmacogenomic information sources, including the Food and Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Dutch Pharmacogenetics Working Group (DPWG), the Pharmacogene Variation Consortium (PharmVar), and curated articles from the biomedical literature database PubMed, to provide accurate, up-to-date evidence in one centralized location. Users can submit pharmacogenomic test results to PGXI and rapidly query and identify relevant gene-drug associations and conditions linked to specific genotypes.

“To better personalize therapies, reduce treatment-related side effects, and improve drug efficacy, scientific and translational researchers need to translate complex pharmacogenomic data into evidence-backed insights,” said Dominic John, Head of QIAGEN Digital Insights. “Traditionally, this process has been largely manual, requiring researchers to search through information dispersed across multiple databases, drug labels, and publications. By adding PGXI to our industry-leading portfolio of expert-curated databases, we are streamlining and accelerating this critical process by offering a single, authoritative source of information, verified and continuously updated, allowing users to make informed decisions with confidence.”

PGXI is transforming precision medicine by dramatically speeding up the process of analyzing how a person’s genes affect their response to medications. What used to take hours or days can now be done in just minutes, without the need for expensive technical support or complex software. PGXI automatically processes genetic information, identifying key details like haplotypes (groups of genes inherited from one parent) and diplotypes (combinations of haplotypes from both parents). This helps map out how these genes influence someone’s response to certain medications, following well-established guidelines. Users then receive a clear, standardized output of results that can be easily integrated into existing systems, making it faster and easier for researchers to use genetic insights to optimize drug development and delivery.

As a pioneer in bioinformatics, QIAGEN Digital Insights (QDI) empowers researchers and clinicians with cutting-edge tools that unlock the full potential of molecular data. With over 25 years of experience in the industry, 90,000 users worldwide, and 4 million profiled patient cases, QDI is committed to accelerating breakthroughs in science and healthcare by providing intuitive, scalable solutions that transform complex biological information into clear, actionable insights. The QIAGEN Knowledge Base stands as the world’s largest, most trusted source of expert-curated genomic information, supporting national precision medicine programs and global research initiatives that are shaping the future of personalized healthcare.

For more information about QIAGEN’s PGXI knowledgebase visit: https://digitalinsights.qiagen.com/pgxi/

PGXI is a knowledgebase subsystem designed for integration into broader workflows or systems and is not intended as a standalone finished product for direct clinical use.

About QIAGEN Digital Insights

QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. QDI has over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3 million profiled patient cases, and over 40 billion scientific data points. The portfolio includes expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights. Learn more at https://digitalinsights.qiagen.com/.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.